| Literature DB >> 33761253 |
Gianni Chessari1, Ian R Hardcastle2, Jong Sook Ahn1, Burcu Anil3, Elizabeth Anscombe3, Ruth H Bawn2, Luke D Bevan1, Timothy J Blackburn2, Ildiko Buck1, Celine Cano2, Benoit Carbain2, Juan Castro1, Ben Cons1, Sarah J Cully2, Jane A Endicott4, Lynsey Fazal1, Bernard T Golding2, Roger J Griffin2, Karen Haggerty2, Suzannah J Harnor2, Keisha Hearn1, Stephen Hobson2, Rhian S Holvey1, Steven Howard1, Claire E Jennings4, Christopher N Johnson1, John Lunec4, Duncan C Miller2, David R Newell4, Martin E M Noble4, Judith Reeks1, Charlotte H Revill2, Christiane Riedinger3, Jeffrey D St Denis1, Emiliano Tamanini1, Huw Thomas4, Neil T Thompson1, Mladen Vinković1, Stephen R Wedge4, Pamela A Williams1, Nicola E Wilsher1, Bian Zhang2, Yan Zhao4.
Abstract
Inhibition of murine double minute 2 (MDM2)-p53 protein-protein interaction with small molecules has been shown to reactivate p53 and inhibit tumor growth. Here, we describe rational, structure-guided, design of novel isoindolinone-based MDM2 inhibitors. MDM2 X-ray crystallography, quantum mechanics ligand-based design, and metabolite identification all contributed toward the discovery of potent in vitro and in vivo inhibitors of the MDM2-p53 interaction with representative compounds inducing cytostasis in an SJSA-1 osteosarcoma xenograft model following once-daily oral administration.Entities:
Year: 2021 PMID: 33761253 DOI: 10.1021/acs.jmedchem.0c02188
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446